Abstract
We report the identification of an FBXW7 mutation in a patient with adenocarcinoma of the lung, whose tumor had previously been shown to be EGFR and ALK wild type and who had previously progressed on multiple lines of systemic therapy. She experienced both clinical and radiographic benefit from treatment with the mTOR inhibitor temsirolimus.
Keywords:
FBXW7 mutation; Lung adenocarcinoma; Next generation sequencing; Temsirolimus; mTOR inhibitor.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / genetics
-
Adenocarcinoma / radiotherapy
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / metabolism*
-
Drug Resistance, Neoplasm
-
F-Box Proteins / genetics
-
F-Box Proteins / metabolism*
-
F-Box-WD Repeat-Containing Protein 7
-
Female
-
Glutamates / administration & dosage
-
Glutamates / adverse effects
-
Guanine / administration & dosage
-
Guanine / adverse effects
-
Guanine / analogs & derivatives
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / radiotherapy
-
Middle Aged
-
Molecular Targeted Therapy
-
Motor Activity / drug effects
-
Mutation / genetics
-
Neoplasm Metastasis
-
Pemetrexed
-
Recurrence
-
Remission Induction
-
Sirolimus / administration & dosage
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives*
-
TOR Serine-Threonine Kinases / metabolism
-
Ubiquitin-Protein Ligases / genetics
-
Ubiquitin-Protein Ligases / metabolism*
-
Weight Gain / drug effects
Substances
-
Cell Cycle Proteins
-
F-Box Proteins
-
F-Box-WD Repeat-Containing Protein 7
-
FBXW7 protein, human
-
Glutamates
-
Pemetrexed
-
Guanine
-
temsirolimus
-
Carboplatin
-
Ubiquitin-Protein Ligases
-
TOR Serine-Threonine Kinases
-
Sirolimus